Your AI-Trained Oncology Knowledge Connection!
Video
Author(s):
Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non–small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.
Heather Greene, a nurse practitioner at West Cancer Center, discusses the most common immune-related adverse events (AEs) in patients with non—small cell lung cancer (NSCLC), and whether or not these AEs vary between agents.
Immune-related AEs can occur anywhere in the body, but they typically manifest on the skin and in the gastrointestinal tract and endocrine system. Rare side effects include pneumonitis and nephritis. It can be difficult to differentiate between immune-related AEs and other symptoms, notes Greene.
Immune-related AEs tend to be lumped together as immune checkpoint inhibitors. We tend to focus on the PD-1/PD-L1 AEs which are generally the same, says Greene. They tend to have the same side effect profiles. There is however some increase in toxicity when PD-L1 inhibitors are combined with CTLA-4 inhibitors.
May 1st 2025 - May 2nd 2026
Apr 30th 2025 - May 1st 2026
Apr 30th 2025 - May 1st 2026
May 2nd 2025 - Jun 7th 2025
May 1st 2025 - Jun 6th 2025
May 1st 2025 - May 2nd 2026
Apr 30th 2025 - May 1st 2026
Apr 30th 2025 - May 1st 2026
May 2nd 2025 - Jun 7th 2025
May 1st 2025 - Jun 6th 2025
May 1st 2025 - May 2nd 2026
Apr 30th 2025 - May 1st 2026
Apr 30th 2025 - May 1st 2026
Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study
Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC
Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC
2 Commerce Drive
Cranbury, NJ 08512